Cite
HARVARD Citation
Schöffski, P. et al. (2020). Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. European journal of cancer. pp. 62-74. [Online].